Where Will Aarey Drugs & Pharmaceuticals Share Price Be in the Next 3 Years?

The Aarey Drugs & Pharmaceuticals share price forecast for the next 3 years is a question on many investors’ minds as the stock trades at Rs 83.8 on 10 July 2026, within a 52 week range of Rs 50.3 to Rs 100. This article lays out a scenario based Aarey Drugs & Pharmaceuticals share price outlook for 2027, 2028 and 2030, built on the company’s fundamentals, sector trends and the key risks that could change the trajectory. Rather than a single number, the focus here is on the range of outcomes and the assumptions behind each one.

Click Here – Get Free Investment Predictions

Aarey Drugs & Pharmaceuticals Company Overview

Aarey Drugs and Pharmaceuticals is a bulk drug and API manufacturer producing active pharmaceutical ingredients for the domestic and export pharmaceutical industry. Understanding the business model is the first step in framing any credible Aarey Drugs & Pharmaceuticals share price forecast, because the durability of earnings ultimately decides where the stock trades.

Company	Aarey Drugs & Pharmaceuticals
NSE Ticker	AAREYDRUGS
CMP (10 July 2026)	Rs 83.8
52 Week High	Rs 100
52 Week Low	Rs 50.3
Market Cap	Rs 238 Cr
Stock PE	59.8
Book Value	Rs 53
ROE	2.75%
ROCE	5.58%
Dividend Yield	0%

Where Does Aarey Drugs & Pharmaceuticals Share Price Stand Today?

The stock currently trades about 16 percent below its 52 week high of Rs 100, which means the market has already tempered some of its optimism. For anyone building a Aarey Drugs & Pharmaceuticals share price forecast, this correction matters for the Aarey Drugs & Pharmaceuticals share price forecast starting point, because entry valuations have a large bearing on 3 year returns.

At the current price, Aarey Drugs & Pharmaceuticals commands a market capitalisation of Rs 238 Cr and trades at a price to earnings multiple of 59.8. The company generates a return on equity of 2.75% and a return on capital employed of 5.58%, which places it in the category of businesses with a recovering profitability profile. These numbers anchor the Aarey Drugs & Pharmaceuticals share price forecast scenarios that follow. How the broader Nifty 50 index trades over this period will also influence the multiple investors are willing to assign to the stock.

Aarey Drugs & Pharmaceuticals Share Price Forecast: Key Growth Drivers for the Next 3 Years

Four forces are likely to shape the Aarey Drugs & Pharmaceuticals share price forecast between now and 2030, and together they explain most of the dispersion in this Aarey Drugs & Pharmaceuticals share price forecast. Each is discussed below with its likely direction of impact.

Earnings Trajectory and Return Ratios

Stock prices ultimately follow earnings. With a recovering profitability profile at present, the pace at which profits compound over FY27 to FY30 will be the single biggest determinant of the Aarey Drugs & Pharmaceuticals share price forecast actually playing out. Consistent earnings delivery tends to expand valuation multiples, while misses compress them quickly.

Structural Tailwinds in Indian Pharmaceuticals

The Indian pharmaceutical market continues to grow in high single to low double digits, supported by chronic disease prevalence, better diagnosis rates and premiumisation of therapies. Companies with strong brand equity and field force productivity, like Aarey Drugs & Pharmaceuticals, are positioned to grow ahead of the market. Sector trends are visible in the Nifty Pharma index, which serves as a useful barometer for the space.

Within the space, investors often benchmark Aarey Drugs & Pharmaceuticals against peers such as Aarti Pharmalabs, Alembic Pharmaceuticals and Bajaj Healthcare on growth and valuations before forming a view on the Aarey Drugs & Pharmaceuticals share price forecast.

Company Specific Catalysts

The bull case for Aarey Drugs & Pharmaceuticals rests on rising API demand from domestic formulators and export opportunities as global supply chains diversify. If these play out on schedule, the Aarey Drugs & Pharmaceuticals share price forecast for 2030 could gravitate toward the upper end of the scenario range discussed below.

Macro Environment and Liquidity

The RBI rate cycle, FII flows into Indian equities and overall market valuations will influence the multiple investors are willing to pay. A benign macro backdrop supports the optimistic end of any Aarey Drugs & Pharmaceuticals share price forecast, while global risk aversion would do the opposite to the Aarey Drugs & Pharmaceuticals share price outlook.

Aarey Drugs & Pharmaceuticals Share Price Forecast 2027, 2028 and 2030: Scenario Analysis

The table below presents a scenario based Aarey Drugs & Pharmaceuticals share price forecast using compounded annual growth assumptions applied to the current market price of Rs 83.8. These are illustrative ranges, not point predictions, and actual outcomes can fall outside them.

Year	Bear Case	Base Case	Bull Case	Assumption
2027	Rs 86	Rs 94	Rs 100	2% to 14% CAGR on CMP
2028	Rs 88	Rs 100	Rs 115	2% to 14% CAGR on CMP
2030	Rs 92	Rs 120	Rs 150	2% to 14% CAGR on CMP

In the base case scenario of this Aarey Drugs & Pharmaceuticals share price forecast, the 2030 level works out to roughly Rs 120, implying steady compounding from today’s levels. The bull case of Rs 150 assumes rising API demand from domestic formulators and export opportunities as global supply chains diversify delivers ahead of expectations, while the bear case of Rs 92 captures a scenario where growth stalls. That is an outcome band of about 10 percent to 79 percent over the period.

Consult a SEBI Registered Investment Advisor Before Acting on Any Forecast

Bull Case vs Bear Case for Aarey Drugs & Pharmaceuticals Share Price

The Bull Case

The optimistic Aarey Drugs & Pharmaceuticals share price forecast assumes rising API demand from domestic formulators and export opportunities as global supply chains diversify. Combined with supportive sector conditions, this could lift both earnings and the valuation multiple, pushing the stock toward Rs 150 by 2030.

The Bear Case

The cautious view centres on the fact that API pricing is commodity like and competition from larger Chinese and Indian producers pressures margins. If these pressures dominate, the Aarey Drugs & Pharmaceuticals share price forecast would skew toward the lower band and the stock could stagnate near Rs 92 even by 2030, underperforming broader indices.

Key Risks That Could Change the Aarey Drugs & Pharmaceuticals Share Price Outlook

• Execution risk: Delays in strategy execution or capacity plans would push the earnings trajectory below the base case assumed in this Aarey Drugs & Pharmaceuticals share price forecast.
• Valuation risk: At a PE of 59.8, any earnings disappointment can trigger sharp multiple compression before fundamentals stabilise.
• Sector risk: API pricing is commodity like and competition from larger Chinese and Indian producers pressures margins.
• Macro risk: A global slowdown, adverse FII flows or unexpected rate moves would compress equity valuations across the market.
• Regulatory risk: Policy, tax or compliance changes affecting the sector can alter the earnings outlook with little warning.

Is Aarey Drugs & Pharmaceuticals Worth Watching for the Long Term?

For long term investors, the relevant question is not just where the Aarey Drugs & Pharmaceuticals share price forecast lands in 2030 or what any single Aarey Drugs & Pharmaceuticals share price forecast says today, but whether the business can compound capital through cycles. The company’s positioning around rising API demand from domestic formulators and export opportunities as global supply chains diversify gives it a credible growth story, while the risks outlined above define what must be monitored each quarter.

Investors should track quarterly earnings, management commentary and sector data rather than anchoring to any single number from a Aarey Drugs & Pharmaceuticals share price outlook. Historically, staying focused on business fundamentals has served investors better than chasing price targets, and consulting a SEBI registered advisor before investing remains the prudent approach.

Download the Univest iOS App or Univest Android App to track Aarey Drugs & Pharmaceuticals share price live.

Conclusion

The Aarey Drugs & Pharmaceuticals share price forecast for the next 3 years spans Rs 92 to Rs 150 by 2030 under the scenarios discussed, with a base case near Rs 120. Any credible Aarey Drugs & Pharmaceuticals share price forecast must be updated as facts change, and the path will be decided by earnings delivery, rising API demand from domestic formulators and export opportunities as global supply chains diversify and the broader market environment. Treat these ranges as a framework for thinking, not a promise of outcomes, and revisit the assumptions as new results come in. Consult a SEBI registered investment advisor before making any investment decision.

What is the Aarey Drugs & Pharmaceuticals share price forecast for the next 3 years?

Ans. The Aarey Drugs & Pharmaceuticals share price forecast for the next 3 years is scenario based rather than a single number. By 2030, the illustrative range spans Rs 92 in the bear case to Rs 150 in the bull case, with a base case near Rs 120, depending on earnings delivery and market conditions.

What is the Aarey Drugs & Pharmaceuticals share price forecast for 2027?

Ans. For 2027, the scenario range works out to Rs 86 to Rs 100, with a base case around Rs 94. This assumes compounding on the current price of Rs 83.8 and is illustrative, not a guaranteed outcome.

What is the Aarey Drugs & Pharmaceuticals share price forecast for 2028?

Ans. The 2028 scenario range is Rs 88 to Rs 115, with the base case near Rs 100. Actual levels will depend on earnings growth, sector trends and overall market valuations at the time.

What is the current share price of Aarey Drugs & Pharmaceuticals?

Ans. As of 10 July 2026, Aarey Drugs & Pharmaceuticals trades at around Rs 83.8 on the NSE, within a 52 week range of Rs 50.3 to Rs 100. Prices change continuously during market hours, so check live quotes before acting.

Is Aarey Drugs & Pharmaceuticals a good stock for the long term?

Ans. Aarey Drugs & Pharmaceuticals has a credible long term story built on rising API demand from domestic formulators and export opportunities as global supply chains diversify, but it also carries risks since API pricing is commodity like and competition from larger Chinese and Indian producers pressures margins. Long term suitability depends on your risk profile and portfolio, so consult a SEBI registered investment advisor before investing.

What is the Aarey Drugs & Pharmaceuticals share price outlook for 2030?

Ans. The Aarey Drugs & Pharmaceuticals share price outlook for 2030 spans Rs 92 to Rs 150 across bear and bull scenarios. Where the stock actually lands will be driven by profit growth, valuation multiples and macro conditions closer to that date.

What are the key risks to the Aarey Drugs & Pharmaceuticals share price forecast?

Ans. The main risks are execution delays, valuation compression from the current PE of 59.8, sector specific pressures, macro shocks and regulatory changes. Any of these can push the stock below the base case scenario discussed in this article.